Search Prime Grants

W81XWH2210762

Project Grant

Overview

Grant Description
Combination of HBV immunotherapy with shRNA-mediated PD-1/PDL checkpoint inhibition for treatment of chronic HBV.
Awardee
Carogen
Grant Program (CFDA)
12.420 - Military Medical Research and Development
Awarding Agency
U.S. Army Medical Research Acquisition Activity (USAMRAA) [DoD - USA - MEDCOM - MRDC]
Funding Agency
Medical Command (MEDCOM) [DoD - USA]
Place of Performance
Hamden, Connecticut 065183025 United States
Geographic Scope
Single Zip Code
Related Opportunity
0011744156
Carogen was awarded HBV Immunotherapy with shRNA-PD-1/PDL for Chronic HBV Project Grant W81XWH2210762 worth $5,515,484 from Medical Command in September 2022 with work to be completed primarily in Hamden Connecticut United States. The grant has a duration of 3 years and was awarded through assistance program 12.420 Military Medical Research and Development.

Status
(Ongoing)

Last Modified 9/21/22

Period of Performance
9/15/22
Start Date
9/14/25
End Date
54.0% Complete

Funding Split
$5.5M
Federal Obligation
$0.0
Non-Federal Obligation
$5.5M
Total Obligated
100.0% Federal Funding
0.0% Non-Federal Funding

Activity Timeline

Interactive chart of timeline of amendments to W81XWH2210762

Additional Detail

Award ID FAIN
W81XWH2210762
SAI Number
None
Award ID URI
None
Awardee Classifications
Small Business
Other
Awarding Office
W81XWH W4PZ USA MED RSCH ACQUIS ACT
Funding Office
W91ZSQ W03J HQ CO USA MED DEV MAT CM
Awardee UEI
JNMNVKEUU2Y3
Awardee CAGE
6TGS8
Performance District
03
Senators
Richard Blumenthal
Christopher Murphy
Representative
Rosa DeLauro

Budget Funding

Federal Account Budget Subfunction Object Class Total Percentage
Defense Health Program, Defense (097-0130) Department of Defense-Military Grants, subsidies, and contributions (41.0) $5,155,484 100%
Modified: 9/21/22